No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
0.9% sodium chloride |
Sodium chloride |
D02056 |
- |
- |
3件: 6, 14, 51 |
2 |
1-(6-benzothiazolylsulfonyl)-5-chloro-1h-indole-2-butanoic acid |
Indole |
- |
- |
- |
1件: 51 |
3 |
1-22460 |
- |
- |
- |
- |
1件: 51 |
4 |
Abatacept |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
5 |
Abituzumab |
Abituzumab |
- |
- |
- |
1件: 51 |
6 |
Abituzumab 1500 mg |
Abituzumab |
- |
- |
- |
1件: 51 |
7 |
Abituzumab 500 mg |
Abituzumab |
- |
- |
- |
1件: 51 |
8 |
Abr-215757 |
- |
- |
- |
- |
2件: 49, 51 |
9 |
Acetaminophen |
Acetaminophen |
D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
11件: 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
10 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
11 |
Acetylcysteine |
Acetylcysteine |
D00221 |
- |
- |
14件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 111, 164, 233, 298, 299 |
12 |
Acetylsalicylic acid |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
3件: 13, 46, 51 |
13 |
Acotiamide |
Acotiamide |
- |
- |
- |
1件: 51 |
14 |
Act-293987 |
- |
- |
- |
- |
2件: 51, 86 |
15 |
Adempas |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
4件: 51, 86, 225, 299 |
16 |
Administration of rituximab and methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 51 |
17 |
Aimspro |
- |
- |
- |
- |
2件: 13, 51 |
18 |
Ajulemic acid |
Ajulemic acid |
D11312 |
1件: CNR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 50, 51, 299 |
19 |
Albumin |
- |
- |
- |
- |
2件: 2, 51 |
20 |
Alemtuzumab |
Alemtuzumab |
D02802 |
- |
- |
13件: 13, 15, 19, 20, 46, 51, 60, 63, 65, 85, 96, 164, 284 |
21 |
Alginic acid |
Alginic acid |
D02324 |
- |
- |
1件: 51 |
22 |
Allogeneic mesenchymal stem cells (allomsc) |
- |
- |
- |
- |
2件: 51, 53 |
23 |
Alpha-2c ar antagonist |
- |
- |
- |
- |
1件: 51 |
24 |
Alprostadil |
Alprostadil |
D00180, D02705 |
1件: PTGER1 |
4件: Calcium signaling pathway, Human cytomegalovirus infection, Neuroactive ligand-receptor interaction, Pathways in cancer |
2件: 51, 70 |
25 |
Am-01 |
- |
- |
- |
- |
1件: 51 |
26 |
Ambrisentan |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
6件: 51, 84, 85, 86, 88, 211 |
27 |
Amlodipine |
Amlodipine |
D00615, D02914, D07450 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 65, 67, 298 |
28 |
Amlodipine gel |
Amlodipine |
D00615, D02914, D07450 |
4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S |
34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
29 |
Anaerobically cultivated human intestinal microbiota |
- |
- |
- |
- |
1件: 51 |
30 |
Anaerobically cultivated medium |
- |
- |
- |
- |
1件: 51 |
31 |
Anti-human t-lymphocyte immunoglobulin from rabbits |
- |
- |
- |
- |
1件: 51 |
32 |
Anti-pandemic h1n1 influenza vaccine |
- |
- |
- |
- |
5件: 46, 49, 50, 51, 53 |
33 |
Anti-thymocyte globulin |
- |
- |
- |
- |
18件: 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
34 |
Anti-thymocyte globulin, rabbit |
Rabbit |
- |
- |
- |
1件: 51 |
35 |
Asasantin retard |
- |
- |
- |
- |
1件: 51 |
36 |
Asasantin retard ® |
- |
- |
- |
- |
1件: 51 |
37 |
Aspirin |
Acetylsalicylic acid |
D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
38 |
Atorvastatin |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
39 |
Autologous stem cells |
- |
- |
- |
- |
2件: 13, 51 |
40 |
Autologous stemcell transplantation with cd (cluster of differentiation) 34 selected stem cells |
- |
- |
- |
- |
1件: 51 |
41 |
Avid200 |
- |
- |
- |
- |
1件: 51 |
42 |
Aviptadil |
Aviptadil |
- |
- |
- |
4件: 49, 51, 85, 86 |
43 |
Bay63-2521 |
- |
- |
- |
- |
3件: 51, 86, 299 |
44 |
Belimumab |
Belimumab |
D03068 |
1件: TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
8件: 11, 43, 44, 46, 49, 51, 53, 222 |
45 |
Bibf 1120 |
- |
- |
- |
- |
2件: 51, 85 |
46 |
Biopsy |
- |
- |
- |
- |
2件: 19, 51 |
47 |
Blood sample |
- |
- |
- |
- |
12件: 8, 13, 46, 49, 51, 53, 61, 66, 97, 274, 288, 299 |
48 |
Blood samples |
- |
- |
- |
- |
8件: 13, 41, 46, 51, 61, 97, 227, 271 |
49 |
Blood sampling |
- |
- |
- |
- |
4件: 13, 19, 51, 96 |
50 |
Bms-986020 |
- |
- |
- |
- |
2件: 51, 85 |
51 |
Bortezomib |
Bortezomib |
D03150 |
1件: PSMB5 |
1件: Proteasome |
13件: 11, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 288, 331 |
52 |
Bosentan |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 13, 41, 47, 51, 84, 85, 86, 88, 210 |
53 |
Bosentan (tracleer) |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
54 |
Bosentan 125 mg |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
55 |
Bosentan 62.5 mg |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
56 |
Bosentan group |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
57 |
Bosentan monohydrate |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 84, 86, 88 |
58 |
Botox® solution |
- |
- |
- |
- |
1件: 51 |
59 |
Botulinum toxin a |
Botulinum toxin type a |
D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
4件: 13, 51, 149, 226 |
60 |
Botulinum toxin type b |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
3件: 2, 6, 51 |
61 |
Botulinum toxin type b (2500 units / vial) |
Botulinum toxin type b |
D02735 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
1件: 51 |
62 |
Brentuximab vedotin |
Brentuximab vedotin |
D09587 |
10件: TNFRSF8, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 |
4件: Cytokine-cytokine receptor interaction, Gap junction, Pathogenic Escherichia coli infection, Phagosome |
2件: 49, 51 |
63 |
Brodalumab |
Brodalumab |
D10061 |
1件: IL17RA |
2件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway |
2件: 37, 51 |
64 |
Buspirone |
Buspirone |
D00702, D07593 |
2件: DRD2, HTR1A |
10件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
2件: 6, 51 |
65 |
Busulfan |
Busulfan |
D00248 |
- |
- |
13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
66 |
Butanoic acid |
Butyric acid |
D05866 |
- |
- |
3件: 34, 51, 97 |
67 |
C-82 topical gel, 1% |
- |
- |
- |
- |
1件: 51 |
68 |
C225 |
Cetuximab |
D03455 |
1件: EGFR |
45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
2件: 51, 86 |
69 |
Calcium |
Calcium |
- |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
70 |
Calcium channel blockers |
Calcium |
- |
- |
- |
1件: 51 |
71 |
Campath |
Alemtuzumab |
D02802 |
- |
- |
4件: 49, 51, 60, 65 |
72 |
Capillarema |
- |
- |
- |
- |
1件: 51 |
73 |
Cd34 selected autologous hematopoietic cells |
- |
- |
- |
- |
1件: 51 |
74 |
Cd34+sc |
- |
- |
- |
- |
1件: 51 |
75 |
Cetuximab |
Cetuximab |
D03455 |
1件: EGFR |
45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
5件: 34, 51, 86, 89, 331 |
76 |
Chloride |
Chloride ion |
- |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
77 |
Cialis |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 51, 86 |
78 |
Cilostazol |
Cilostazol |
D01896 |
3件: PDE3A, PDE3B, TBXA2R |
14件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 51, 70 |
79 |
Coagulation factor xiii |
Factor xiii (human) |
- |
- |
- |
1件: 51 |
80 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
81 |
Depot leuprolide acetate 3.75 mg |
Leuprolide |
D00989, D08113 |
1件: GNRHR |
2件: GnRH signaling pathway, Neuroactive ligand-receptor interaction |
1件: 51 |
82 |
Digna p144 cream |
- |
- |
- |
- |
1件: 51 |
83 |
Dimethyl fumarate |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
3件: 13, 51, 86 |
84 |
Dimethyl fumarate (dmf) |
Dimethyl fumarate |
D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
3件: 13, 51, 86 |
85 |
Diphenhydramine |
Diphenhydramine |
D00300, D00669, D02419, D03285, D03360, D03854 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
5件: 49, 51, 70, 86, 256 |
86 |
Dipyridamole |
Dipyridamole |
D00302 |
2件: PDE4A, PDE5A |
6件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 46, 49, 51, 66, 224 |
87 |
Divalproex sodium |
- |
- |
- |
- |
1件: 51 |
88 |
Domperidone |
Domperidone |
D01745, D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
5件: 6, 13, 17, 51, 230 |
89 |
Drug treatment |
- |
- |
- |
- |
3件: 51, 74, 271 |
90 |
Ema/chmp/212874/2015 |
- |
- |
- |
- |
1件: 51 |
91 |
Endoprost |
- |
- |
- |
- |
1件: 51 |
92 |
Endoprost - 0.05 mg/0.5 ml concentrato per soluzione per infusione 1 fiala |
- |
- |
- |
- |
1件: 51 |
93 |
Endoprost 50*infus 1f 0,050mg/ |
- |
- |
- |
- |
1件: 51 |
94 |
Endothelin receptor blocker |
- |
- |
- |
- |
1件: 51 |
95 |
Erbitux |
Cetuximab |
D03455 |
1件: EGFR |
45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis |
2件: 51, 86 |
96 |
Esbriet |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
3件: 51, 85, 228 |
97 |
Ex vivo cultured human mesenchymal stem cells |
- |
- |
- |
- |
1件: 51 |
98 |
Fibrogammin |
Fibrinolysin |
D07422 |
- |
- |
2件: 51, 288 |
99 |
Fibrogammin®p, coagulation factor xiii concentrate (human) |
Factor xiii (human), Factor xiii (human) |
- |
- |
- |
1件: 51 |
100 |
Filgrastim |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
25件: 2, 6, 13, 25, 26, 28, 34, 35, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 283, 284, 285, 331 |
101 |
Fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
102 |
Fludarabine phosphate |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
11件: 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285 |
103 |
Fresolimumab |
Fresolimumab |
D09620 |
3件: TGFB1, TGFB2, TGFB3 |
34件: AGE-RAGE signaling pathway in diabetic complications, Amoebiasis, Cell cycle, Cellular senescence, Chagas disease (American trypanosomiasis), Chronic myeloid leukemia, Colorectal cancer, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), FoxO signaling pathway, Gastric cancer, Hepatitis B, Hepatocellular carcinoma, Hippo signaling pathway, Human T-cell leukemia virus 1 infection, Hypertrophic cardiomyopathy (HCM), Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, Leishmaniasis, MAPK signaling pathway, Malaria, MicroRNAs in cancer, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, TGF-beta signaling pathway, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
3件: 51, 222, 274 |
104 |
G-csf |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
12件: 6, 13, 16, 49, 51, 60, 65, 85, 96, 284, 285, 331 |
105 |
Glivec |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 51, 86 |
106 |
Glpg1690 |
- |
- |
- |
- |
2件: 51, 85 |
107 |
Glycyrrhizin |
Glycyrrhizic acid |
D00157 |
- |
- |
1件: 51 |
108 |
Gm-csf |
Regramostim |
D05712 |
1件: CSF2RA |
4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
4件: 11, 46, 51, 229 |
109 |
Gsk2330811 |
- |
- |
- |
- |
2件: 51, 96 |
110 |
Gsk2330811 solution for injection, 100mg/ml |
- |
- |
- |
- |
1件: 51 |
111 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 |
112 |
Hidonac*ev 1fl 5g 25ml |
- |
- |
- |
- |
1件: 51 |
113 |
High-dose intravenous immunoglobulin (venoglobulin-ih) |
Immune globulin human |
- |
- |
- |
1件: 51 |
114 |
Human anti-transforming growth factor beta-1 monoclonal antibody |
- |
- |
- |
- |
1件: 51 |
115 |
Hyperimmune caprine serum |
- |
- |
- |
- |
1件: 51 |
116 |
Ifetroban |
Ifetroban |
D04500 |
1件: TBXA2R |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
3件: 51, 86, 113 |
117 |
Igpro10 |
- |
- |
- |
- |
3件: 14, 51, 65 |
118 |
Igpro20 |
- |
- |
- |
- |
3件: 14, 51, 65 |
119 |
Ilomedin |
- |
- |
- |
- |
1件: 51 |
120 |
Iloprost |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
4件: 51, 84, 85, 86 |
121 |
Iloprost injection, for intravenous use |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 51 |
122 |
Iloprost low dose |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 51 |
123 |
Iloprost sale di trometamolo |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 51 |
124 |
Iloprost therapy up to 2 ng/kg x min |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 51 |
125 |
Iloprost trometamol |
Iloprost |
D02721 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 51 |
126 |
Imatinib |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
127 |
Imatinib mesylate |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 13, 28, 34, 51, 86 |
128 |
Imnovid 1 mg hard capsules |
Pomalidomide |
D08976 |
2件: IL6, TNF |
76件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
1件: 51 |
129 |
Indocyanine green |
- |
- |
- |
- |
4件: 46, 51, 235, 291 |
130 |
Indole |
Indole |
- |
- |
- |
1件: 51 |
131 |
Injection of allogeneic mesenchymal stem cells |
- |
- |
- |
- |
1件: 51 |
132 |
Injection of autologous stromal vascular fraction |
- |
- |
- |
- |
1件: 51 |
133 |
Interleukin 2 |
Human interleukin-2 |
- |
- |
- |
9件: 46, 49, 51, 56, 63, 95, 96, 97, 271 |
134 |
Intravenous immunoglobulin |
Immune globulin human |
- |
- |
- |
16件: 2, 11, 14, 17, 18, 35, 38, 39, 49, 51, 63, 65, 85, 164, 296, 309 |
135 |
Iontophoresis of treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
1件: 51 |
136 |
Iv cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 51 |
137 |
Iva337 |
- |
- |
- |
- |
1件: 51 |
138 |
Ivig |
Immune globulin human |
- |
- |
- |
12件: 11, 13, 14, 17, 18, 50, 51, 63, 65, 85, 164, 296 |
139 |
Jbt-101 |
- |
- |
- |
- |
4件: 49, 50, 51, 299 |
140 |
Kd025 |
- |
- |
- |
- |
2件: 51, 85 |
141 |
Khk4827 |
- |
- |
- |
- |
2件: 37, 51 |
142 |
Lactate |
Lactic acid |
D00111 |
- |
- |
1件: 51 |
143 |
Lactobacillus |
- |
- |
- |
- |
1件: 51 |
144 |
Lenabasum |
- |
- |
- |
- |
3件: 50, 51, 299 |
145 |
Lenabasum 20 mg |
- |
- |
- |
- |
3件: 50, 51, 299 |
146 |
Lenabasum 20 mg powder in capsule |
- |
- |
- |
- |
1件: 51 |
147 |
Lenabasum 5 mg |
- |
- |
- |
- |
3件: 50, 51, 299 |
148 |
Lenabasum 5 mg powder in capsule |
- |
- |
- |
- |
1件: 51 |
149 |
Leuprolide |
Leuprolide |
D00989, D08113 |
1件: GNRHR |
2件: GnRH signaling pathway, Neuroactive ligand-receptor interaction |
5件: 1, 2, 3, 51, 76 |
150 |
Lipitor |
Atorvastatin |
D00258, D00887, D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
1件: 51 |
151 |
Mabthera |
- |
- |
- |
- |
15件: 11, 13, 35, 46, 50, 51, 53, 61, 63, 64, 65, 83, 162, 222, 271 |
152 |
Macitentan |
Macitentan |
D10135 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 51, 85, 86, 88, 210 |
153 |
Mesenchymal stem cells |
- |
- |
- |
- |
11件: 2, 6, 13, 20, 49, 51, 60, 96, 222, 274, 299 |
154 |
Mesenchymal stromal cells |
- |
- |
- |
- |
6件: 36, 51, 96, 97, 274, 284 |
155 |
Mesna |
Coenzyme m |
- |
- |
- |
9件: 13, 44, 45, 49, 51, 60, 65, 96, 164 |
156 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
157 |
Methylprednisolon |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
4件: 13, 51, 66, 222 |
158 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
159 |
Methylprednisolone sodium succinate |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 13, 46, 51 |
160 |
Metronidazole |
Metronidazole |
D00409, D05016, D05017 |
- |
- |
8件: 46, 51, 63, 94, 95, 96, 97, 291 |
161 |
Mhsct |
- |
- |
- |
- |
1件: 51 |
162 |
Microgynon |
- |
- |
- |
- |
2件: 13, 51 |
163 |
Mizoribine |
Mizoribine |
D01392 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
7件: 49, 51, 53, 66, 94, 222, 224 |
164 |
Mycophenolate |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
33件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
165 |
Mycophenolate mofetil |
Mycophenolate mofetil |
D00752, D05094, D05095 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
166 |
Mycophenolic acid |
Mycophenolic acid |
D05096 |
2件: IMPDH1, IMPDH2 |
3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
7件: 11, 49, 51, 60, 66, 96, 222 |
167 |
N-acetylcysteine (nac) |
Acetylcysteine |
D00221 |
- |
- |
2件: 51, 299 |
168 |
Neovasculgen |
- |
- |
- |
- |
1件: 51 |
169 |
Neupogen |
Filgrastim |
D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
4件: 13, 28, 51, 285 |
170 |
Nilotinib |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
5件: 6, 8, 34, 51, 86 |
171 |
Nilotinib (tasigna) |
Nilotinib |
D08953 |
4件: ABL1, KIT, PDGFRA, PDGFRB |
33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
1件: 51 |
172 |
Nintedanib |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
4件: 51, 85, 89, 228 |
173 |
Nivolumab |
Nivolumab |
D10316 |
1件: PDCD1 |
3件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway |
10件: 13, 26, 41, 46, 49, 50, 51, 53, 96, 97 |
174 |
Null |
- |
- |
- |
- |
17件: 6, 13, 14, 15, 28, 37, 46, 49, 51, 63, 86, 90, 96, 97, 107, 145, 271 |
175 |
Ofev |
Nintedanib |
D10481 |
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB |
34件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway |
4件: 51, 85, 89, 228 |
176 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
177 |
Omeprazole 20mg |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 51 |
178 |
Oral ifetroban |
Ifetroban |
D04500 |
1件: TBXA2R |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
2件: 51, 86 |
179 |
Oral treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 51, 86 |
180 |
Orencia |
Abatacept |
D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
9件: 46, 50, 51, 53, 65, 84, 96, 97, 271 |
181 |
Orm-12471 |
- |
- |
- |
- |
1件: 51 |
182 |
Orm-12471 30mg |
- |
- |
- |
- |
1件: 51 |
183 |
Orm-12741 |
- |
- |
- |
- |
1件: 51 |
184 |
Other vasodilator |
- |
- |
- |
- |
1件: 51 |
185 |
Ozone |
Ozone |
- |
- |
- |
2件: 49, 51 |
186 |
P144 |
- |
- |
- |
- |
1件: 51 |
187 |
P144. cytokines inhibitors |
- |
- |
- |
- |
1件: 51 |
188 |
Paquinimod |
Paquinimod |
- |
- |
- |
2件: 49, 51 |
189 |
Part b open-label extension |
- |
- |
- |
- |
1件: 51 |
190 |
Peripheral blood stem cells |
- |
- |
- |
- |
1件: 51 |
191 |
Phosphate |
Phosphate ion |
- |
- |
- |
29件: 2, 3, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 256, 283, 284, 285, 286, 299 |
192 |
Phosphodiesterase inhibitors |
- |
- |
- |
- |
1件: 51 |
193 |
Physiological saline |
- |
- |
- |
- |
1件: 51 |
194 |
Pirfenidone |
Pirfenidone |
D01583 |
6件: CCL2, IL10, IL1A, IL1B, IL6, TNF |
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
10件: 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
195 |
Placebo |
- |
- |
- |
- |
20件: 3, 6, 13, 14, 40, 46, 49, 50, 51, 66, 67, 79, 85, 86, 88, 96, 97, 144, 149, 226 |
196 |
Platelet gel |
- |
- |
- |
- |
1件: 51 |
197 |
Plerixafor |
Plerixafor |
D08971 |
1件: CXCR4 |
12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor |
4件: 51, 65, 285, 299 |
198 |
Pletal |
Cilostazol |
D01896 |
3件: PDE3A, PDE3B, TBXA2R |
14件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
199 |
Pomalidomide |
Pomalidomide |
D08976 |
2件: IL6, TNF |
76件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy (DCM), EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pertussis, Prion diseases, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
6件: 28, 34, 51, 85, 227, 331 |
200 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
201 |
Prednisolone 5 mg |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 46, 51 |
202 |
Prednisolone and taper |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 51 |
203 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
204 |
Privigen |
Immune globulin human |
- |
- |
- |
4件: 11, 14, 51, 65 |
205 |
Prostanoids |
- |
- |
- |
- |
1件: 51 |
206 |
Prucalopride |
Prucalopride |
D09205 |
1件: HTR4 |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway |
3件: 13, 51, 96 |
207 |
Prucalopride succinate |
Prucalopride |
D09205 |
1件: HTR4 |
4件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse, cAMP signaling pathway |
1件: 51 |
208 |
Qax576 |
- |
- |
- |
- |
4件: 51, 85, 96, 98 |
209 |
Rabbit |
Rabbit |
- |
- |
- |
7件: 13, 49, 51, 60, 65, 96, 285 |
210 |
Rabeprazole |
Rabeprazole |
D00724, D08463 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
2件: 2, 51 |
211 |
Rapamycin |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
16件: 2, 15, 34, 35, 46, 49, 51, 60, 61, 67, 86, 89, 158, 256, 278, 279 |
212 |
Ratg |
- |
- |
- |
- |
2件: 13, 51 |
213 |
Rbatg |
- |
- |
- |
- |
2件: 51, 96 |
214 |
Recombinant humanized anti-human monoclonal antibody directed against the il-6r |
- |
- |
- |
- |
2件: 46, 51 |
215 |
Relaxin |
- |
- |
- |
- |
1件: 51 |
216 |
Resolor*28cpr riv 2mg |
- |
- |
- |
- |
1件: 51 |
217 |
Resunab, ajulemic acid, anabasum |
Ajulemic acid |
D11312 |
1件: CNR2 |
1件: Neuroactive ligand-receptor interaction |
3件: 50, 51, 299 |
218 |
Rilonacept |
Rilonacept |
D06635 |
2件: IL1A, IL1B |
41件: AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
4件: 51, 106, 107, 266 |
219 |
Ringer lactate |
Lactic acid |
D00111 |
- |
- |
1件: 51 |
220 |
Riociguat |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
6件: 51, 84, 86, 88, 225, 299 |
221 |
Riociguat (adempas, bay63-2521) |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
3件: 51, 86, 88 |
222 |
Riociguat coated tablet 0.5 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 51 |
223 |
Riociguat coated tablet 1.0 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 51 |
224 |
Riociguat coated tablet 1.5 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 51 |
225 |
Riociguat coated tablet 2.0 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 51 |
226 |
Riociguat coated tablet 2.5 mg |
Riociguat |
D09572 |
3件: GUCY1A1, GUCY1A2, GUCY1B1 |
11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 51 |
227 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
228 |
Ro 47-0203 |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 51, 85, 86, 88 |
229 |
Ro 487-7533/f10-04 |
- |
- |
- |
- |
4件: 41, 46, 51, 107 |
230 |
Ro47-0203 / act-050088 |
- |
- |
- |
- |
2件: 51, 86 |
231 |
Ro487-7533/f10-04 |
- |
- |
- |
- |
2件: 46, 51 |
232 |
Roactemra |
- |
- |
- |
- |
5件: 41, 46, 51, 86, 107 |
233 |
Roactemra 162 mg |
- |
- |
- |
- |
2件: 46, 51 |
234 |
Rosemary |
Rosemary |
- |
- |
- |
1件: 51 |
235 |
Rosuvastatin |
Rosuvastatin |
D01915, D08492 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
8件: 6, 46, 49, 51, 79, 96, 271, 299 |
236 |
Saccharomyces boulardii oral tablet |
- |
- |
- |
- |
1件: 51 |
237 |
Sar100842 |
- |
- |
- |
- |
1件: 51 |
238 |
Sar156597 |
- |
- |
- |
- |
2件: 51, 85 |
239 |
Sar156597 (act14604) |
- |
- |
- |
- |
1件: 51 |
240 |
Selexipag |
Selexipag |
D09994 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 70, 84, 86, 88 |
241 |
Sildenafil |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
15件: 6, 46, 50, 51, 85, 86, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
242 |
Sildenafil 20mg |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 51, 86 |
243 |
Sildenafil 20mg and bosentan 62.5mg |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
2件: 51, 86 |
244 |
Sildenafil citrate |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
4件: 51, 85, 86, 225 |
245 |
Sildenafil therapy |
Sildenafil |
D02229, D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
1件: 51 |
246 |
Simvastatin |
Simvastatin |
D00434 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
19件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 162, 195, 265, 298, 299, 310 |
247 |
Sinvacor*28cpr riv 20mg |
- |
- |
- |
- |
1件: 51 |
248 |
Sirolimus |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
30件: 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
249 |
Sodium chloride |
Sodium chloride |
D02056 |
- |
- |
13件: 6, 11, 13, 14, 34, 46, 51, 168, 193, 227, 228, 288, 299 |
250 |
Sodium fluoride |
Sodium fluoride |
D00943 |
- |
- |
1件: 51 |
251 |
Sodium fluoride 18f |
Sodium fluoride |
D00943 |
- |
- |
1件: 51 |
252 |
Solu-medrone |
- |
- |
- |
- |
3件: 51, 83, 162 |
253 |
Soluble ve cadherin |
- |
- |
- |
- |
1件: 51 |
254 |
Standard of care |
- |
- |
- |
- |
8件: 6, 13, 14, 49, 51, 64, 79, 85 |
255 |
Steroids |
- |
- |
- |
- |
7件: 46, 50, 51, 63, 66, 96, 97 |
256 |
Sti571 |
Imatinib |
D01441, D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
2件: 51, 86 |
257 |
Stromal vascular fraction |
- |
- |
- |
- |
1件: 51 |
258 |
Study of the gene expression profile |
- |
- |
- |
- |
1件: 51 |
259 |
Tacrolimus |
Tacrolimus |
D00107, D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
29件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
260 |
Tadalafil |
Tadalafil |
D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
6件: 6, 51, 75, 84, 86, 113 |
261 |
Tadalafil and ambrisentan upfront combination therapy |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 51, 86 |
262 |
Terguride |
Terguride |
D01348 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
2件: 51, 86 |
263 |
Terguride hydrogenmaleate |
Terguride |
D01348 |
2件: DRD2, PRL |
12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway |
1件: 51 |
264 |
Thalidomide |
Thalidomide |
D00754 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
18件: 2, 16, 20, 28, 49, 51, 53, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 331 |
265 |
Thiotepa |
Thiotepa |
D00583 |
- |
- |
11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 |
266 |
Thymoglobulin |
- |
- |
- |
- |
4件: 36, 51, 60, 96 |
267 |
Thymoglobuline |
- |
- |
- |
- |
4件: 13, 36, 51, 65 |
268 |
Tocilizumab |
Tocilizumab |
D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
269 |
Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs) |
Tocilizumab |
D02596 |
1件: IL6R |
11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
1件: 51 |
270 |
Tofacitinib |
Tofacitinib |
D09970 |
4件: JAK1, JAK2, JAK3, TYK2 |
34件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis |
9件: 46, 49, 50, 51, 84, 96, 97, 107, 271 |
271 |
Tracleer |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
8件: 13, 51, 84, 85, 86, 88, 210, 211 |
272 |
Tracleer*125mg 56cpr riv. |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
273 |
Tracleer*56cpr riv 125mg |
Bosentan |
D01227, D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 51 |
274 |
Transdihydrolisuride |
- |
- |
- |
- |
2件: 51, 86 |
275 |
Treprostinil |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
5件: 51, 84, 85, 86, 88 |
276 |
Treprostinil diethanolamine |
Treprostinil |
D06213 |
1件: PTGIR |
3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction |
2件: 51, 86 |
277 |
Trimebutine |
Trimebutine |
D08639 |
2件: OPRK1, OPRM1 |
3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
1件: 51 |
278 |
Trometamol |
Tromethamine |
D00396 |
- |
- |
1件: 51 |
279 |
Urine sample |
- |
- |
- |
- |
3件: 49, 51, 61 |
280 |
Ut-15 sr |
- |
- |
- |
- |
1件: 51 |
281 |
Ut-15c sr |
- |
- |
- |
- |
2件: 51, 86 |
282 |
Ut-15c-sr |
- |
- |
- |
- |
1件: 51 |
283 |
Vib7734 |
- |
- |
- |
- |
4件: 49, 50, 51, 53 |
284 |
Vivomixx probiotics |
- |
- |
- |
- |
1件: 51 |
285 |
Volibris |
Ambrisentan |
D07077 |
1件: EDNRA |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 51, 86, 88 |
286 |
Yellow fever vaccine |
Yellow fever vaccine |
D06347 |
- |
- |
7件: 40, 44, 46, 50, 51, 52, 53 |
287 |
Yellow fever vaccine (17d) |
Yellow fever vaccine |
D06347 |
- |
- |
7件: 40, 44, 46, 50, 51, 52, 53 |